CrossrefInfokarte
Importance of higher infliximab trough level maintenance compared with the HLA-DQA1*05 polymorphism in preventing anti-infliximab antibodies and loss of response to infliximab
Inflammatory Bowel Diseases · 2026-11-01 · 32 (11) · 2232-2236
DOI: 10.1093/ibd/izag108 ↗Abstract
Summary In this single-center cohort of patients with inflammatory bowel disease (IBD) managed with proactive infliximab monitoring, HLA-DQA1*05 was not associated with immunogenicity or loss of response, whereas higher infliximab (IFX) drug levels and concomitant immunomodulator therapy independently reduced the risk of both outcomes.
EUVIMED